Source: http://medline.ru/public/art/tom11/art3.html
Timestamp: 2019-04-19 11:05:38+00:00

Document:
ТОМ 11, СТ. 3 (стр. 19-26) | февраль 2010 г.
1. Asa SL, Ezzat S. 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocrim Rev. 19:798-827.III Всероссийская научно-практическая конференция "Актуальные проблемы нейроэндокринологии" Москва, 6-7 октября 2003 г.
2. Monson JP. The epidemiology of endocrine tumours. Endocrine-Related Cancer, 7,2000,29-36 selective pressure expressed at the uterine level. Am. J. Reprod. Immunol., 1999, V. 41, R 5-22.
3. Fournier A., Berrino R, Riboli E. et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer, 2005, V. 114, P. 448- 454.
4. Franke H. R., Kole S., Ciftci Z., Haanen C, Vermes I. In vitro effects of estradiol, 25 dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells. Cancer Lett, 2003, V. 190, P. 113-118.
5. Joachim R., Zenclussen A. C, Polgar B. et al. Steroids. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response, 2003, V. 68, P. 931-940.
6. Nielsen M., Thomsen J. L., Primdahl S. et al. Br. J. Cancer. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies, 1987, V. 56, P. 814-819.
7. Raghupathy R., Al Mutawa E., Makhseed M. et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG, 2005, V. 112, P. 1096-1101.
8. Szekeres-Bartho J., Polgar В., Kozma N. et al. Progesterone-dependent immunomodulation. Chem. Immunol. Allergy, 2005, V. 89, R 118-125.
9. Weiderpass E., Adami H. 0., Baron J. A. et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst, 1999, V. 91, P. 1131-1137.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.